Esaxerenone (CS-3150)

Catalog No.E0704 Batch:E070401

Print

Technical Data

Formula

C22H21F3N2O4S

Molecular Weight 466.48 CAS No. 1632006-28-0
Solubility (25°C)* In vitro DMSO 93 mg/mL (199.36 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Esaxerenone (CS-3150), a selective nonsteroidal mineralocorticoid receptor (MR) antagonist, binds to mineralocorticoid receptor and inhibits (3)H-aldosterone binding to mineralocorticoid receptor with an IC50 value of 9.4 nM. Esaxerenone (CS-3150) also has the property of increasing the likelihood of albuminuria returning to normal levels and reducing progression of albuminuria to higher levels.
Targets
Mineralocorticoid Receptor [1]
(in the radioligand-binding assay)
9.4 nM
In vitro

Esaxerenone is a selective nonsteroidal mineralocorticoid receptor antagonist, which inhibits aldosterone-induced transcriptional activation of human mineralocorticoid receptor with no agonistic effect on mineralocorticoid receptor, and has no antagonistic or agonistic effect on glucocorticoid receptor, androgen receptor and progesterone receptor even at the high concentration of 5 μM.[1]

In vivo

In adrenalectomized rats, single oral administration of esaxerenone suppressed aldosterone-induced decrease in urinary Na(+)/K(+) ratio, an index of in vivo mineralocorticoid receptor activation, and this suppressive effect is more potent and longer-lasting than that of spironolactone and eplerenone.[1]

Protocol (from reference)

Cell Assay:

[1]

  • Cell lines

    293 A cells

  • Concentrations

    1 nM

  • Incubation Time

    24 h

  • Method

    For the transient transfection experiments, 293 A cells are inoculated on 100 mm dishes (4.5×106 cells/dish) and cultured for 24 h in DMEM with 10% heat-inactivated FBS in 5% CO2 at 37 ℃. Then, the cells are co-transfected with each of expression plasmid and 3×GRE-Luc2P by lipofection using Lipofectamine 2000. After transfection, the cells are harvested and transferred into 96-well plates (1.0×104 cells/well) containing a DMEM with 10% heat-inactivated charcoal-stripped FBS followed by incubation for 24 h. Serial dilutions of esaxerenone with or without 1 nM of the corresponding ligands for each receptor are added and further incubated for approximately 24 h. The luciferase activity of each well is measured in a multimode assay system.

Animal Study:

[1]

  • Animal Models

    bilateral adrenalectomized rat

  • Dosages

    0.3, 1 and 3 mg/kg

  • Administration

    o.g.

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.